MET inhibitor
MET receptor tyrosine kinase inhibitor
- Suppresses tumors with MET exon-14 skipping or amplification
- Blocks the MET receptor tyrosine kinase
- Peripheral edema is the characteristic effect
Drugs with this mechanism (1)
- Capmatinib — MET inhibitor for lung cancers with exon-14 skipping; photosensitivity and pneumonitis matter.
Self-check
- Which tumor alterations support MET inhibitor activity?
MET exon-14 skipping or amplification. - Which characteristic adverse effect accompanies MET inhibition?
Peripheral edema.
All mechanisms · Open MET inhibitor in the interactive console ↗